Value of 18F-FES PET in solving clinical dilemmas in breast cancer patients: a retrospective study
J Boers, N Loudini, CL Brunsch, SA Koza… - Journal of Nuclear …, 2021 - Soc Nuclear Med
Breast cancer (BC) is a heterogeneous disease in which estrogen receptor (ER) expression
plays an important role in most tumors. A clinical dilemma may arise when a metastasis …
plays an important role in most tumors. A clinical dilemma may arise when a metastasis …
[HTML][HTML] Joint EANM-SNMMI guideline on the role of 2-[18F] FDG PET/CT in no special type breast cancer
SC Vaz, JPP Woll, F Cardoso, D Groheux… - European Journal of …, 2024 - Springer
Purpose To provide an organized, international, state-of-the-art, and multidisciplinary
guideline, led by experts of two nuclear medicine societies (EANM and SNMMI) and …
guideline, led by experts of two nuclear medicine societies (EANM and SNMMI) and …
18F-FDG PET/CT for staging and restaging of breast cancer
Many studies have pointed out the role of 18 F-FDG PET/CT (or 18 F-FDG PET) in patients
with clinical stage III or II breast cancer. 18 F-FDG PET/CT might advantageously replace …
with clinical stage III or II breast cancer. 18 F-FDG PET/CT might advantageously replace …
[HTML][HTML] Co-clinical FDG-PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer
S Roy, TD Whitehead, S Li, FO Ademuyiwa… - European journal of …, 2022 - Springer
Purpose We sought to exploit the heterogeneity afforded by patient-derived tumor xenografts
(PDX) to first, optimize and identify robust radiomic features to predict response to therapy in …
(PDX) to first, optimize and identify robust radiomic features to predict response to therapy in …
(18) F-FDG-PET/CT in evaluating response to therapy in solid tumors: where we are and where we can go.
K Herrmann, MR Benz, BJ Krause… - The Quarterly Journal …, 2011 - europepmc.org
In the past, enormous public and private investments have been made to reduce cancer
incidence and mortality. Despite some improvements over the last 10 years, the overall …
incidence and mortality. Despite some improvements over the last 10 years, the overall …
18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer
J Duch, D Fuster, M Muñoz, PL Fernández… - European journal of …, 2009 - Springer
Purpose The aim of this study was to prospectively evaluate 18 F-FDG PET/CT in predicting
response to neoadjuvant chemotherapy in large primary breast cancer. Methods Fifty …
response to neoadjuvant chemotherapy in large primary breast cancer. Methods Fifty …
Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments
Eighteen years ago, the EORTC PET criteria standardized for the first time response
assessment by FDG PET. Response assessment by FDG PET has been further developed …
assessment by FDG PET. Response assessment by FDG PET has been further developed …
Degree of tumor FDG uptake correlates with proliferation index in triple negative breast cancer
Abstract Purpose 2-Deoxy-2-[F-18] fluoro-D-glucose (FDG) uptake may be a useful
surrogate marker for proliferation index, but the correlation has not always been clear-cut …
surrogate marker for proliferation index, but the correlation has not always been clear-cut …
18 F-FDG PET/CT for initial staging in breast cancer patients – Is there a relevant impact on treatment planning compared to conventional staging modalities?
J Krammer, A Schnitzer, CG Kaiser, KA Buesing… - European …, 2015 - Springer
Objective To evaluate the impact of whole-body 18 F-FDG PET/CT on initial staging of breast
cancer in comparison to conventional staging modalities. Methods This study included 102 …
cancer in comparison to conventional staging modalities. Methods This study included 102 …